<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00722956</url>
  </required_header>
  <id_info>
    <org_study_id>D1710C00025</org_study_id>
    <secondary_id>EudraCt nr 2008-001725-33</secondary_id>
    <nct_id>NCT00722956</nct_id>
  </id_info>
  <brief_title>Drug Interaction Study - Assess Pharmacokinetics of Both AZD5672 and Atorvastatin</brief_title>
  <official_title>A Phase I, Single Centre, Open-label Study to Assess the Pharmacokinetics of Both AZD5672 (Steady-state) and Atorvastatin (Single Dose) When Co Administered in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the pharmacokinetics of both AZD5672 (steady-state) and
      atorvastatin (single dose) when co administered in healthy volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK variables</measure>
    <time_frame>Frequent sampling occasions during study periods</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety variables (adverse events, blood pressure, pulse, safety lab)</measure>
    <time_frame>During the whole treatment periods</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD5672 + atorvastatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD5672</intervention_name>
    <description>100 mg once daily, 10 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin</intervention_name>
    <description>one single dose of 40 mg on day 10</description>
    <arm_group_label>1</arm_group_label>
    <other_name>LipitorÂ®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent prior to any study specific procedures.

          -  Females should not be of childbearing potential

          -  Clinically normal physical and laboratory findings as judged by the investigator,
             including negative test results for drug-of-abuse, alcohol and cotinine at the
             Screening Visit and/or admission (Day -1) of each study period, and negative test
             results

        Exclusion Criteria:

          -  Any clinically significant disease or disorder which, in the opinion of the
             investigator, may either put the subject at risk because of participation in the
             study, or may influence the results of the study, or the subject's ability to
             participate

          -  Known allergy to atorvastatin (or other statins) or previous complications to
             atorvastatin therapy.

          -  Participation in a clinical study involving an investigational product within 5
             half-lives of active moieties of the last dose of investigational product or 3 months
             prior to first dosing (whichever is longer).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rod Hepburn</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D, Charnwood, UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maura Fallon</last_name>
    <role>Principal Investigator</role>
    <affiliation>PAREXEL Clinical Pharmacology Research Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2008</study_first_submitted>
  <study_first_submitted_qc>July 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2008</study_first_posted>
  <last_update_submitted>November 30, 2010</last_update_submitted>
  <last_update_submitted_qc>November 30, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Mark Layton, MD, PhD, Medical Science Director</name_title>
    <organization>AstraZeneca R&amp;D Alderely Park</organization>
  </responsible_party>
  <keyword>atorvastatin</keyword>
  <keyword>AZD5672</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>N-(1-(3-(3,5-difluorophenyl)-3-(4-methanesulfonylphenyl)propyl)piperidin-4-yl)-N-ethyl-2-(4-methanesulfonylphenyl)acetamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

